TherapeuticsMD
TherapeuticsMD, Inc. operates as a women’s health care product company in the United States. The last earnings update was 53 days ago. More info.
Add to Portfolio Compare Print
- TherapeuticsMD has significant price volatility in the past 3 months.
TXMD Share Price and Events
7 Day Returns
1 Year Returns
TXMD Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| TherapeuticsMD (TXMD) | -7% | -18.5% | -17.2% | -25.9% | -49.8% | -3.6% |
| US Pharmaceuticals | -3.3% | -5.9% | -2% | 7.1% | 5.1% | 14.4% |
| US Market | -0.3% | 2.2% | 8.5% | 7% | 37.7% | 46.8% |
1 Year Return vs Industry and Market
- TXMD underperformed the Pharmaceuticals industry which returned 7.1% over the past year.
- TXMD underperformed the Market in United States of America which returned 7% over the past year.
Value
Is TherapeuticsMD undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
TherapeuticsMD
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for TherapeuticsMD.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 6 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7.5% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.67 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.674 (1 + (1- 21%) (7.19%)) |
0.807 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.81 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.807 * 5.96%) |
7.54% |
Discounted Cash Flow Calculation for NasdaqGS:TXMD using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for TherapeuticsMD is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 7.54%) |
|
|---|---|---|---|
| 2019 | -161.73 | Analyst x3 | -150.39 |
| 2020 | 9.60 | Analyst x2 | 8.30 |
| 2021 | 126.80 | Analyst x4 | 101.95 |
| 2022 | 383.58 | Analyst x5 | 286.78 |
| 2023 | 338.87 | Analyst x3 | 235.58 |
| 2024 | 312.26 | Est @ -7.85% | 201.86 |
| 2025 | 297.66 | Est @ -4.68% | 178.92 |
| 2026 | 290.35 | Est @ -2.45% | 162.29 |
| 2027 | 287.74 | Est @ -0.9% | 149.55 |
| 2028 | 288.28 | Est @ 0.19% | 139.33 |
| Present value of next 10 years cash flows | $1,314.17 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $288.28 × (1 + 2.73%) ÷ (7.54% – 2.73%) |
$6,154.47 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $6,154.47 ÷ (1 + 7.54%)10 |
$2,974.48 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $1,314.17 + $2,974.48 |
$4,288.65 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $4,288.65 / 241.16 |
$17.78 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $17.78 |
| Current discount | Discount to share price of
$4.23
= -1 x ($4.23 - $17.78) / $17.78 |
76.2% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- TherapeuticsMD's share price is below the future cash flow value, and at a moderate discount (> 20%).
- TherapeuticsMD's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for TherapeuticsMD's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
TherapeuticsMD's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | $-0.59 |
| NasdaqGS:TXMD Share Price ** | NasdaqGS (2019-04-18) in USD | $4.23 |
| United States of America Pharmaceuticals Industry PE Ratio | Median Figure of 29 Publicly-Listed Pharmaceuticals Companies | 18.42x |
| United States of America Market PE Ratio | Median Figure of 3,081 Publicly-Listed Companies | 18.17x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of TherapeuticsMD.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:TXMD Share Price ÷ EPS (both in USD) = 4.23 ÷ -0.59 |
-7.18x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- TherapeuticsMD is loss making, we can't compare its value to the US Pharmaceuticals industry average.
- TherapeuticsMD is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
TherapeuticsMD's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -7.18x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts |
60.6%per year |
| United States of America Pharmaceuticals Industry PEG Ratio | Median Figure of 23 Publicly-Listed Pharmaceuticals Companies | 1.5x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.56x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for TherapeuticsMD, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
TherapeuticsMD's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | $0.41 |
| NasdaqGS:TXMD Share Price * | NasdaqGS (2019-04-18) in USD | $4.23 |
| United States of America Pharmaceuticals Industry PB Ratio | Median Figure of 181 Publicly-Listed Pharmaceuticals Companies | 3.44x |
| United States of America Market PB Ratio | Median Figure of 5,182 Publicly-Listed Companies | 1.91x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:TXMD Share Price ÷ Book Value per Share (both in USD) = 4.23 ÷ 0.41 |
10.43x |
* Primary Listing of TherapeuticsMD.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- TherapeuticsMD is overvalued based on assets compared to the US Pharmaceuticals industry average.
Value checks
We assess TherapeuticsMD's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) TherapeuticsMD has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- TherapeuticsMD's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- TherapeuticsMD's earnings growth is expected to exceed the United States of America market average.
- TherapeuticsMD's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:TXMD Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts | 60.6% |
| NasdaqGS:TXMD Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts | 47.5% |
| United States of America Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 18.7% |
| United States of America Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 5.1% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 881 | 372 | 381 | 5 |
| 2022-12-31 | 670 | 276 | 291 | 5 |
| 2021-12-31 | 436 | 132 | 132 | 6 |
| 2020-12-31 | 219 | -37 | -49 | 6 |
| 2019-12-31 | 47 | -145 | -159 | 6 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 16 | -107 | -133 |
| 2018-09-30 | 15 | -99 | -115 |
| 2018-06-30 | 16 | -82 | -94 |
| 2018-03-31 | 17 | -75 | -80 |
| 2017-12-31 | 17 | -76 | -77 |
| 2017-09-30 | 17 | -71 | -78 |
| 2017-06-30 | 18 | -73 | -89 |
| 2017-03-31 | 18 | -70 | -90 |
| 2016-12-31 | 19 | -69 | -90 |
| 2016-09-30 | 20 | -70 | -85 |
| 2016-06-30 | 20 | -70 | -79 |
| 2016-03-31 | 21 | -79 | -85 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
All data from TherapeuticsMD Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 1.48 | 2.09 | 0.94 | 4.00 |
| 2022-12-31 | 1.15 | 1.36 | 0.99 | 4.00 |
| 2021-12-31 | 0.51 | 0.66 | 0.35 | 5.00 |
| 2020-12-31 | -0.21 | -0.05 | -0.37 | 4.00 |
| 2019-12-31 | -0.66 | -0.62 | -0.75 | 5.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.59 |
| 2018-09-30 | -0.52 |
| 2018-06-30 | -0.44 |
| 2018-03-31 | -0.38 |
| 2017-12-31 | -0.37 |
| 2017-09-30 | -0.39 |
| 2017-06-30 | -0.45 |
| 2017-03-31 | -0.46 |
| 2016-12-31 | -0.46 |
| 2016-09-30 | -0.44 |
| 2016-06-30 | -0.42 |
| 2016-03-31 | -0.47 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if TherapeuticsMD will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess TherapeuticsMD's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
TherapeuticsMD has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has TherapeuticsMD performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- TherapeuticsMD does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare TherapeuticsMD's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare TherapeuticsMD's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
All data from TherapeuticsMD Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 16.10 | -132.62 | 115.99 | 27.30 |
| 2018-09-30 | 15.13 | -114.65 | 94.76 | 31.52 |
| 2018-06-30 | 16.08 | -93.71 | 76.46 | 31.25 |
| 2018-03-31 | 16.57 | -80.17 | 61.62 | 33.17 |
| 2017-12-31 | 16.78 | -76.93 | 57.70 | 33.85 |
| 2017-09-30 | 17.14 | -78.33 | 59.85 | 33.22 |
| 2017-06-30 | 18.26 | -88.69 | 62.52 | 41.45 |
| 2017-03-31 | 18.41 | -90.10 | 58.51 | 46.57 |
| 2016-12-31 | 19.36 | -89.88 | 51.35 | 53.94 |
| 2016-09-30 | 20.50 | -84.52 | 43.65 | 56.86 |
| 2016-06-30 | 20.15 | -78.98 | 35.99 | 58.61 |
| 2016-03-31 | 20.60 | -85.11 | 32.24 | 68.96 |
| 2015-12-31 | 20.14 | -85.08 | 28.72 | 72.04 |
| 2015-09-30 | 18.77 | -83.90 | 25.60 | 72.96 |
| 2015-06-30 | 17.77 | -82.26 | 24.59 | 71.44 |
| 2015-03-31 | 16.67 | -65.93 | 23.26 | 55.49 |
| 2014-12-31 | 15.03 | -54.22 | 22.12 | 43.22 |
| 2014-09-30 | 13.63 | -46.29 | 21.17 | 34.89 |
| 2014-06-30 | 11.74 | -36.12 | 19.58 | 24.38 |
| 2014-03-31 | 10.07 | -31.23 | 19.52 | 17.89 |
| 2013-12-31 | 8.78 | -28.42 | 19.01 | 13.55 |
| 2013-09-30 | 7.15 | -25.77 | 19.39 | 9.07 |
| 2013-06-30 | 5.90 | -22.37 | 17.67 | 6.56 |
| 2013-03-31 | 4.63 | -28.21 | 15.77 | 5.65 |
| 2012-12-31 | 3.82 | -35.12 | 14.07 | 4.49 |
| 2012-09-30 | 3.13 | -38.98 | 11.73 | 2.98 |
| 2012-06-30 | 2.63 | -36.21 | 10.62 | 1.19 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if TherapeuticsMD has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if TherapeuticsMD has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if TherapeuticsMD improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess TherapeuticsMD's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
TherapeuticsMD has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is TherapeuticsMD's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up TherapeuticsMD's finances.
The net worth of a company is the difference between its assets and liabilities.
- TherapeuticsMD is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- TherapeuticsMD's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from TherapeuticsMD Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 97.52 | 73.38 | 161.61 |
| 2018-09-30 | 134.22 | 73.26 | 190.00 |
| 2018-06-30 | 77.55 | 73.14 | 154.39 |
| 2018-03-31 | 107.30 | 0.00 | 107.35 |
| 2017-12-31 | 129.91 | 0.00 | 127.14 |
| 2017-09-30 | 149.48 | 0.00 | 148.29 |
| 2017-06-30 | 93.59 | 0.00 | 96.48 |
| 2017-03-31 | 110.33 | 0.00 | 113.53 |
| 2016-12-31 | 127.49 | 0.00 | 131.53 |
| 2016-09-30 | 146.35 | 0.00 | 147.53 |
| 2016-06-30 | 167.25 | 0.00 | 166.53 |
| 2016-03-31 | 183.37 | 0.00 | 182.10 |
| 2015-12-31 | 63.06 | 0.00 | 64.71 |
| 2015-09-30 | 77.56 | 0.00 | 81.12 |
| 2015-06-30 | 63.01 | 0.00 | 67.25 |
| 2015-03-31 | 87.72 | 0.00 | 91.66 |
| 2014-12-31 | 48.39 | 0.00 | 51.36 |
| 2014-09-30 | 63.60 | 0.00 | 67.00 |
| 2014-06-30 | 37.48 | 0.00 | 35.55 |
| 2014-03-31 | 46.75 | 0.00 | 45.40 |
| 2013-12-31 | 54.70 | 0.00 | 54.19 |
| 2013-09-30 | 62.09 | 0.00 | 59.57 |
| 2013-06-30 | 38.47 | 0.00 | 34.44 |
| 2013-03-31 | 39.94 | 0.10 | 38.78 |
| 2012-12-31 | -1.43 | 3.59 | 1.55 |
| 2012-09-30 | -4.33 | 5.59 | 0.15 |
| 2012-06-30 | -0.70 | 3.54 | 1.33 |
- TherapeuticsMD's level of debt (75.2%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 75.2% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- TherapeuticsMD has sufficient cash runway for 1.3 years based on current free cash flow.
- TherapeuticsMD has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 15.2% each year.
Financial health checks
We assess TherapeuticsMD's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) TherapeuticsMD has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is TherapeuticsMD's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
TherapeuticsMD
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate TherapeuticsMD's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate TherapeuticsMD's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| United States of America Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 2.8% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2009 Stocks | 2.4% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as TherapeuticsMD has not reported any payouts.
- Unable to verify if TherapeuticsMD's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess TherapeuticsMD's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can TherapeuticsMD afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) TherapeuticsMD has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $2,983,955 |
| AGE | 47 |
| TENURE AS CEO | 7.5 years |
CEO Bio
Mr. Robert G. Finizio, also known as Rob, is the Co-Founder of TherapeuticsMD, Inc. and has been its Chief Executive Officer since October 4, 2011. Mr. Finizio served as the Principal Accounting Officer of TherapeuticsMD, Inc. As co-founder of VitaMed, from April 2008 to October 4, 2011 Mr. Finizio served as its Chief Executive Officer. From August 2001 to February 2008, he co-founded and served as President of Care Fusion, LLC. Mr. Finizio co-founded Care Fusion, Inc. in 2001 and served as its Vice President of Business Development and Chief Executive Officer. He was responsible for overseeing strategic initiatives and corporate partnerships of Care Fusion, Inc. He has over 10 years of experience in healthcare and healthcare informatics. Mr. Finizio has extensive experience with commercial and government contracting and large-scale account management. He served as Regional Sales Manager and Sales Director of Omnicell, where he sold enterprise scale clinical workflow solutions. Mr. Finizio worked in sales and sales management for Endoscopy Specialists Inc. He served as the Chairman of the Board of Vitamed and TherapeuticsMD, Inc. since October 4, 2011. He has been a Director of TherapeuticsMD, Inc. since October 4, 2011. He served as a Director of Vitamed from April 2008 to October 2011. A member of HIMSS, Mr. Finizio earned a Bachelor of Science degree in Pre-Med from the University of Miami in Coral Gables, FL.
CEO Compensation
- Rob's compensation has increased whilst company is loss making.
- Rob's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the TherapeuticsMD management team in years:
- The average tenure for the TherapeuticsMD management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team
Rob Finizio
Co-Founder
$3M
47
7.5 yrs
John C. Milligan
President
$2M
56
7.5 yrs
Brian Bernick
Co-Founder
$1M
50
Dan Cartwright
CFO & Treasurer
$1M
60
7.5 yrs
Mitchell Krassan
Executive VP and Chief Strategy & Performance Officer
$1M
52
7.5 yrs
Jason Spitz
Vice President of Commercial Development & Operations
Joel Krasnow
Chief Scientific Officer and Head of Regulatory Department
5.3 yrs
Adam Miller
Chief Information Officer
1.1 yrs
Nichol Ochsner
Vice President of Investor Relations
1.3 yrs
Marlan Walker
General Counsel & Chief Development Officer
3.1 yrs
Board of Directors Tenure
Average tenure and age of the TherapeuticsMD board of directors in years:
- The tenure for the TherapeuticsMD board of directors is about average.
Board of Directors
Tommy Thompson
Chairman of the Board
$363K
76
6.9 yrs
Rob Finizio
Co-Founder
$3M
47
7.5 yrs
John C. Milligan
President
$2M
56
7.5 yrs
Brian Bernick
Co-Founder
$1M
50
7.5 yrs
Cooper Collins
Independent Director
$249K
39
7.2 yrs
Robert LaPenta
Independent Director
$254K
49
7.2 yrs
Nick Segal
Independent Director
$230K
36
7.2 yrs
Jules Musing
Independent Director
$229K
71
5.9 yrs
Angus Russell
Independent Director
$234K
62
4.1 yrs
Marty Carroll
Independent Director
$241K
69
4.1 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 01. Mar 19 | Sell | Jules Musing | Individual | 27. Feb 19 | 27. Feb 19 | -17,400 | $5.80 | $-100,920 | ||
| 23. Aug 18 | Buy | Thomas Thompson | Individual | 21. Aug 18 | 21. Aug 18 | 4,000 | $5.53 | $22,100 | ||
Management checks
We assess TherapeuticsMD's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) TherapeuticsMD has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Introducing TherapeuticsMD (NASDAQ:TXMD), The Stock That Dropped 17% In The Last Five Years
Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … Over five years, TherapeuticsMD grew its revenue at 5.8% per year.
Simply Wall St - – Full articleIs TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Balance Sheet A Threat To Its Future?
Help shape the future of investing tools and receive a $20 prize! … Investors are always looking for growth in small-cap stocks like TherapeuticsMD, Inc. … However, an important fact which most ignore is: how financially healthy is the business?
Simply Wall St - – Full articleIs TherapeuticsMD, Inc.'s (NASDAQ:TXMD) CEO Paid Enough Relative To Peers?
First, this article will compare CEO compensation with compensation at similar sized companies. … Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. … How Does Rob Finizio's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleHow Does Investing In TherapeuticsMD, Inc. (NASDAQ:TXMD) Impact The Volatility Of Your Portfolio?
(NASDAQ:TXMD), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Simply Wall St - – Full articleTherapeuticsMD Inc's (NASDAQ:TXMD) Shift From Loss To Profit
With the latest financial year loss of -US$77m and a trailing-twelve month of -US$94m, the US$1.1b market-cap amplifies its loss by moving further away from its breakeven target. … Many investors are wondering the rate at which TXMD will turn a profit, with the big question being “when will the company breakeven?” … Below I will provide a high-level summary of the industry analysts’ expectations for TXMD
Simply Wall St - – Full articleHow Should You Think About TherapeuticsMD Inc's (NASDAQ:TXMD) Risks?
The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … Not every stock is exposed to the same level of market risk.
Simply Wall St - – Full articleWhere TherapeuticsMD Inc (NASDAQ:TXMD) Stands In Terms Of Earnings Growth Against Its Industry
After looking at TherapeuticsMD Inc's (NASDAQ:TXMD) latest earnings update (31 March 2018), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … As a long-term investor I tend to focus on earnings trend, rather than a single number at one point in time. … TXMD is loss-making, with the most recent trailing twelve-month earnings of -US$80.17m (from 31 March 2018), which compared to last year has become
Simply Wall St - – Full articleBest NasdaqGS Growth Stocks
NasdaqGS:TXMD Future Profit Nov 12th 17 Grupo Financiero Galicia S.A. … LABL’s projected future profit growth is a robust 38.51%, with an underlying 85.08% growth from its revenues expected over the upcoming years. … NasdaqGS:LABL Future Profit Nov 12th 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
Simply Wall St - – Full articleCompany Info
Description
TherapeuticsMD, Inc. operates as a women’s health care product company in the United States. The company’s hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Details
| Name: | TherapeuticsMD, Inc. |
| TXMD | |
| Exchange: | NasdaqGS |
| Founded: | 2008 |
| $1,020,114,604 | |
| 241,161,845 | |
| Website: | http://www.therapeuticsmd.com |
| Address: |
TherapeuticsMD, Inc. 6800 Broken Sound Parkway NW, Third Floor, Boca Raton, Florida, 33487, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | TXMD | Common Stock | Nasdaq Global Select | US | USD | 05. Oct 2011 | |
| DB | 29T | Common Stock | Deutsche Boerse AG | DE | EUR | 05. Oct 2011 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/04/21 00:25 |
| End of day share price update: | 2019/04/18 00:00 |
| Last estimates confirmation: | 2019/04/18 |
| Last earnings filing: | 2019/02/27 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
